Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 28.85B -2.4% |
| Revenue (ttm) | 3.25B +82.6% |
| Net Income | 407.42M |
| EPS | 2.99 |
| Shares Out | n/a |
| PE Ratio | 70.81 |
| Forward PE | 25.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203 |
| Open | 280.77 |
| Previous Close | 284.22 |
| Day's Range | 280.20 - 291.14 |
| 52-Week Range | 273.00 - 500.21 |
| Beta | 0.27 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo... [Read more]
News
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” webin...
Alnylam, GENESIS Pharma expand commercial partnership
GENESIS Pharma announced the expansion of its longstanding commercial partnership with Alnylam (ALNY) Pharmaceuticals. The extended agreement broadens the geographical reach of the collaboration to in...
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region.
Alnylam Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management targets 25% revenue CAGR and 30% operating margin through 2030, driven by TTR franchise leadership and pipeline diversification. AMVUTTRA leads near-term growth, with nucresiran and other assets advancing. U.S. access remains strong, and R&D investment is prioritized.
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500
The index added two companies on Friday, but more are likely to be added in the near future.
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech Inceptive in a deal worth up to $2 billion to use AI to speed up discovery of RNA-based medicines.
Alnylam, Inceptive form strategic AI collaboration
The company states: “Alnylam (ALNY) Pharmaceuticals and Inceptive Nucleics, Inc. announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valu...
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models...
Alnylam Pharmaceuticals Transcript: AGM 2026
The meeting approved all board proposals, including director elections and auditor ratification. Strong financial results were highlighted, with Q1 product revenue up 121% year-over-year and ambitious growth and innovation targets set through 2030.
Alnylam Issues 2025 Corporate Responsibility Report
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The...
Alnylam initiated with a Buy at Citi
Citi initiated coverage of Alnylam (ALNY) with a Buy rating and $380 price target The expanded launch of Amvuttra for ATTR-CM has “no doubt been impressive,” says the analyst, who…
Alnylam Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company is leveraging its RNAi platform to drive profitable growth, with strong AMVUTTRA sales and ambitious 2026 guidance. Pipeline investments focus on next-generation TTR therapies and new indications, while robust cash reserves support both internal and external innovation.
Alnylam announces new analyses from HELIOS-B study of vutrisiran
Alnylam (ALNY) announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, adding to the gro...
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in pa...
MBX Biosciences appoints Mark Soued as chief commercial officer.
MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as senior VP, head of U.S. at Alnylam Pharmaceuticals (ALNY). Published first on…
Alnylam to Webcast Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following ...
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients wit...
Alnylam price target raised to $370 from $360 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Alnylam (ALNY) to $370 from $360 and keeps an Equal Weight rating on the shares.
Alnylam price target lowered to $447 from $448 at Bernstein
Bernstein lowered the firm’s price target on Alnylam (ALNY) to $447 from $448 and keeps an Outperform rating on the shares. The firm notes Amvuttra beat consensus by 5%. Shares…
Alnylam reports Q1 EPS $1.99, consensus $1.47
Reports Q1 revenue $1.167B, consensus $1.12B. “2026 is off to a strong start for Alnylam (ALNY) with the end of the first quarter marking one year since the U.S. launch…
Alnylam Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw record net product revenues exceeding $1 billion, driven by robust TTR franchise growth and strong rare disease performance. The company reiterated full-year guidance, advanced its pipeline, and maintained high gross margins despite royalty headwinds.
Alnylam Pharmaceuticals Quarterly report: Q1 2026
Alnylam Pharmaceuticals has published its Q1 2026 quarterly earnings report on April 30, 2026.
Alnylam Pharmaceuticals Slides: Q1 2026
Alnylam Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Alnylam Pharmaceuticals Earnings release: Q1 2026
Alnylam Pharmaceuticals released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.